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Background
Cardiac magnetic resonance imaging (CMR) is a powerful tool to identify the arrhythmia substrate in patients with ischemic or non-ischemic cardiomyopathy. However, the performance and diagnostic yield of CMR in pre-ablation evaluation for ventricular arrhythmia in patients without known structural heart disease was still unknown. In the present study, we sought to investigate the performance of CMR in identifying the potential structural heart disease or substrate for ventricular arrhythmia in pre-ablation patients.
Methods
CMR was performed in a series of consecutive patients (average age 45.8±16.9 years) with premature ventricular contraction or paroxysmal ventricular tachycardia referred for trans-catheter ablation. None of the patients had any known structural heart disease. CMR protocol included regular cine, rest perfusion and late gadolinium enhancement imaging. CMR image was interpreted by two experienced experts who were blinded to the echocardiography findings and clinical diagnosis.
Results
The average left ventricular ejection fraction of the whole cohort was 54.9±11.1% and right ventricular ejection fraction was 45.6±15.6%. there was no significant difference in LVEDVI, LVESVI, LVMASSI,LVEF, RVEDVI, RVESVI and RVEF between patients with PVC and VT. There was 17/40(42.7%) abnormal global or regional wall motion findings by CMR cine. myocardial late gadolinium enhancement (LGE) was found in 10/40 (25%) cases. The cumulative abnormalities rate was 45% through CMR, whereas abnormal findings was only confirmed in 6/40(15%) in the same group of patients. In addition, in patients with LGE, RVEDVI, RVESVI and RVEF were significantly decreased than the patients without LGE.
Conclusions
CMR was a powerful tool to identify the potential structural heart disease in patients with ventricular arrhythmia before ablation. Comprehensive CMR examination appeared to be more sensitive than echocardiography in detecting structural abnormalities in patients with ventricular tachycardia without known cardiomyopathy, before ablation therapy is planned. 
